Compound Evidence File
#EC-2026-0945
Clenbuterol
Filed under Oral Tablets. The bureau holds 117 laboratory returns for this compound from 48 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
48 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 10.0 | 9.9 | 10.0 | 28 Feb 2026 | 10 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 21 Dec 2025 | 28 Jun 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 16 Jan 2026 | 24 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Apr 2026 | 6 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 10.0 | 10.0 | 2 Jun 2026 | 13 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 9.9 | 10.0 | 1 Jan 2026 | 6 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 4 May 2026 | 4 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 28 Nov 2025 | 11 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 10.0 | 10.0 | 10.0 | 20 Jan 2026 | 17 Mar 2026 |
| Pura PeptidesCASE #VI-2026-0307 | X | 1 | 10.0 | 10.0 | 10.0 | 20 Jun 2025 | 20 Jun 2025 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 9.9 | 9.9 | 9.9 | 21 Mar 2026 | 11 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Mar 2026 | 4 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 9.9 | 9 May 2026 | 7 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Mar 2026 | 11 May 2026 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 9.4 | 9.4 | 9.4 | 17 Dec 2024 | 17 Dec 2024 |
| HkRoidsCASE #VI-2026-0784 | X | 1 | 9.4 | 9.4 | 9.4 | 28 Mar 2025 | 28 Mar 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 9.1 | 8.7 | 10.0 | 21 May 2026 | 21 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 8.4 | 7.6 | 10.0 | 23 May 2026 | 23 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | X | 3 | 8.4 | 7.5 | 9.7 | 2 Jul 2025 | 25 May 2026 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 8.3 | 8.3 | 8.3 | 27 Feb 2025 | 27 Feb 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 8.2 | 8.1 | 8.3 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 8.2 | 8.1 | 8.3 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 5 | 7.9 | 6.6 | 9.9 | 24 May 2026 | 24 May 2026 |
| Shenzhen Loga Tech LG LOGACASE #VI-2026-0920 | X | 2 | 7.6 | 6.5 | 8.7 | 3 Jul 2025 | 19 Jan 2026 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 7.4 | 7.4 | 7.4 | 17 Dec 2024 | 17 Dec 2024 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 2 | 7.3 | 7.1 | 7.5 | 14 Jan 2025 | 23 May 2026 |
| Anlv BiotechnologyCASE #VI-2026-0110 | X | 1 | 7.3 | 7.3 | 7.3 | 14 Jan 2025 | 14 Jan 2025 |
| Zztai PeptideCASE #VI-2026-0192 | C | 3 | 7.2 | 6.8 | 7.5 | 8 Jul 2025 | 24 May 2026 |
| Simple PeptideCASE #VI-2026-0782 | X | 2 | 7.2 | 5.2 | 9.1 | 14 Jan 2025 | 17 May 2026 |
| Kits4lessCASE #VI-2026-0744 | X | 1 | 7.2 | 7.2 | 7.2 | 24 Apr 2025 | 24 Apr 2025 |
| Aavant ResearchCASE #VI-2026-0831 | X | 1 | 7.2 | 7.2 | 7.2 | 21 May 2025 | 21 May 2025 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 2 | 6.8 | 6.8 | 6.9 | 2 Jul 2025 | 20 May 2026 |
| NexaphCASE #VI-2026-0944 | X | 12 | 6.7 | 4.1 | 9.6 | 28 Mar 2025 | 25 May 2026 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 6.7 | 6.7 | 6.7 | 20 Jun 2025 | 20 Jun 2025 |
| Evolve BioPepCASE #VI-2026-0755 | X | 1 | 6.0 | 6.0 | 6.0 | 2 Jul 2025 | 2 Jul 2025 |
| Peptide CraftersCASE #VI-2026-0994 | X | 3 | 5.9 | 5.4 | 6.4 | 20 Jun 2025 | 17 May 2026 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 2 | 5.9 | 4.8 | 7.1 | 3 Jun 2025 | 19 Jan 2026 |
| Elite Research USACASE #VI-2026-0267 | X | 2 | 5.0 | 4.1 | 5.9 | 17 Dec 2024 | 26 Jan 2026 |
| UWA Elite PeptidesCASE #VI-2026-0130 | X | 1 | 4.4 | 4.4 | 4.4 | 6 May 2025 | 6 May 2025 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 4.0 | 4.0 | 4.0 | 16 Mar 2025 | 16 Mar 2025 |
| LSPLCASE #VI-2026-0523 | X | 1 | 3.9 | 3.9 | 3.9 | 6 May 2025 | 6 May 2025 |
| Modern AminosCASE #VI-2026-0635 | X | 1 | 2.9 | 2.9 | 2.9 | 3 Jun 2025 | 3 Jun 2025 |
| Shaanxi Dideu MedichemCASE #VI-2026-0499 | X | 1 | 2.8 | 2.8 | 2.8 | 7 May 2025 | 7 May 2025 |
| HK Fat CatCASE #VI-2026-0376 | X | 1 | 1.4 | 1.4 | 1.4 | 20 Jun 2025 | 20 Jun 2025 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.0 | 0.0 | 0.0 | 9 Jun 2025 | 9 Jun 2025 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 0.0 | 0.0 | 0.0 | 9 Jun 2025 | 9 Jun 2025 |
Open any subject to view the batch-level evidence for Clenbuterol alone.